{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:30:57Z","timestamp":1773160257166,"version":"3.50.1"},"reference-count":173,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/QUI\/50006\/2020"],"award-info":[{"award-number":["UID\/QUI\/50006\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>p53 is a transcription factor with a pivotal role in cell homeostasis and fate. Its impairment is a major event in tumor onset and development. In fact, about half of human cancers bear TP53 mutations that not only halt the normal function of p53, but also may acquire oncogenic gain of functions that favor tumorigenesis. Although considered undruggable for a long time, evidence has proven the capability of many compounds to restore a wild-type (wt)-like function to mutant p53 (mutp53). However, they have not reached the clinic to date. Structural studies have strongly contributed to the knowledge about p53 structure, stability, dynamics, function, and regulation. Importantly, they have afforded relevant insights into wt and mutp53 pharmacology at molecular levels, fostering the design and development of p53-targeted anticancer therapies. Herein, we provide an integrated view of mutp53 regulation, particularly focusing on mutp53 structural traits and on targeting agents capable of its reactivation, including their biological, biochemical and biophysical features. With this, we expect to pave the way for the development of improved small molecules that may advance precision cancer therapy by targeting p53.<\/jats:p>","DOI":"10.3390\/cancers13133344","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T22:34:36Z","timestamp":1625438076000},"page":"3344","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Structural and Drug Targeting Insights on Mutant p53"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9378-6043","authenticated-orcid":false,"given":"Ana Sara","family":"Gomes","sequence":"first","affiliation":[{"name":"LAQV\/REQUIMTE, Laborat\u00f3rio de Microbiologia, Departamento de Ci\u00eancias Biol\u00f3gicas, Faculdade de Farm\u00e1cia, Universidade do Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-9998","authenticated-orcid":false,"given":"Helena","family":"Ramos","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Laborat\u00f3rio de Microbiologia, Departamento de Ci\u00eancias Biol\u00f3gicas, Faculdade de Farm\u00e1cia, Universidade do Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8767-1637","authenticated-orcid":false,"given":"Alberto","family":"Inga","sequence":"additional","affiliation":[{"name":"Laboratory of Transcriptional Networks, Department CIBIO, University of Trento, Via Sommarive 9, 38123 Trento, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-4672","authenticated-orcid":false,"given":"Em\u00edlia","family":"Sousa","sequence":"additional","affiliation":[{"name":"Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"},{"name":"CIIMAR-Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Novo Edif\u00edcio do Terminal de Cruzeiros do Porto de Leix\u00f5es, Avenida General Norton de Matos, S\/N, 4450-208 Matosinhos, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9531-4939","authenticated-orcid":false,"given":"Luc\u00edlia","family":"Saraiva","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Laborat\u00f3rio de Microbiologia, Departamento de Ci\u00eancias Biol\u00f3gicas, Faculdade de Farm\u00e1cia, Universidade do Porto, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrm2395","article-title":"Transcriptional control of human p53-regulated genes","volume":"9","author":"Riley","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrc2730","article-title":"The expanding universe of p53 targets","volume":"9","author":"Menendez","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.biochem.77.060806.091238","article-title":"Structural Biology of the Tumor Suppressor p53","volume":"77","author":"Joerger","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.molcel.2012.01.020","article-title":"Distinct Regulatory Mechanisms and Functions for p53-Activated and p53-Repressed DNA Damage Response Genes in Embryonic Stem Cells","volume":"46","author":"Li","year":"2012","journal-title":"Mol. Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1242\/jcs.064501","article-title":"p53 at a glance","volume":"123","author":"Brady","year":"2010","journal-title":"J. Cell Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the Light: The Growing Complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0705-7","article-title":"New therapeutic strategies to treat human cancers expressing mutant p53 proteins","volume":"37","author":"Blandino","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"a028308","DOI":"10.1101\/cshperspect.a028308","article-title":"Structural Evolution and Dynamics of the p53 Proteins","volume":"7","author":"Chillemi","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bph.14572","article-title":"Salvation of the fallen angel: Reactivating mutant p53","volume":"176","author":"Li","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.febslet.2014.03.049","article-title":"Wild type p53 reactivation: From lab bench to clinic","volume":"588","author":"Selivanova","year":"2014","journal-title":"FEBS Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ng1572","article-title":"Temporal dissection of p53 function In Vitro and In Vivo","volume":"37","author":"Christophorou","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_13","first-page":"661","article-title":"Restoration of p53 function leads to tumour regression In Vivo","volume":"445","author":"Ventura","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"a000919","DOI":"10.1101\/cshperspect.a000919","article-title":"The Tumor Suppressor p53: From Structures to Drug Discovery","volume":"2","author":"Joerger","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20758","DOI":"10.1073\/pnas.0909644106","article-title":"Multiple conformations of full-length p53 detected with single-molecule fluorescence resonance energy transfer","volume":"106","author":"Huang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12324","DOI":"10.1073\/pnas.0705069104","article-title":"Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex","volume":"104","author":"Tidow","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1073\/pnas.94.26.14338","article-title":"Thermodynamic stability of wild-type and mutant p53 core domain","volume":"94","author":"Bullock","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.onc.1203434","article-title":"Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy","volume":"19","author":"Bullock","year":"2000","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jmb.2009.11.013","article-title":"Folding of Tetrameric p53: Oligomerization and Tumorigenic Mutations Induce Misfolding and Loss of Function","volume":"395","author":"Lubin","year":"2010","journal-title":"J. Mol. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32526","DOI":"10.1074\/jbc.M604725200","article-title":"Effects of Oncogenic Mutations and DNA Response Elements on the Binding of p53 to p53-binding Protein 2 (53BP2)","volume":"281","author":"Tidow","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-08880-4","article-title":"Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells","volume":"7","author":"Ahn","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8748","DOI":"10.1093\/nar\/gkt630","article-title":"Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions","volume":"41","author":"Eldar","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14675","DOI":"10.1073\/pnas.95.25.14675","article-title":"Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability","volume":"95","author":"Nikolova","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jmb.2008.10.063","article-title":"Structural Basis of Restoring Sequence-Specific DNA Binding and Transactivation to Mutant p53 by Suppressor Mutations","volume":"385","author":"Suad","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/cdd.2010.35","article-title":"p53-family proteins and their regulators: Hubs and spokes in tumor suppression","volume":"17","author":"Collavin","year":"2010","journal-title":"Cell Death Differ."},{"key":"ref_28","first-page":"41","article-title":"The relevance of protein-protein interactions for p53 function: The CPE contribution","volume":"24","author":"Sot","year":"2010","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cell.2009.04.050","article-title":"Modes of p53 Regulation","volume":"137","author":"Kruse","year":"2009","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.18632\/aging.100047","article-title":"The regulation of p53 by phosphorylation: A model for how distinct signals integrate into the p53 pathway","volume":"1","author":"Maclaine","year":"2009","journal-title":"Aging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/humu.23035","article-title":"TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum. Mutat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1073\/pnas.1015520107","article-title":"Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA","volume":"108","author":"Melero","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1073\/pnas.0801353105","article-title":"Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain","volume":"105","author":"Wells","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12937","DOI":"10.1074\/jbc.M108815200","article-title":"Biogenesis of p53 Involves Cotranslational Dimerization of Monomers and Posttranslational Dimerization of Dimers","volume":"277","author":"Nicholls","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jmb.2004.06.071","article-title":"Cooperative binding of tetrameric p53 to DNA","volume":"341","author":"Weinberg","year":"2004","journal-title":"J. Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molcel.2006.05.015","article-title":"Structural Basis of DNA Recognition by p53 Tetramers","volume":"22","author":"Kitayner","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Tebaldi, T., Zaccara, S., Alessandrini, F., Bisio, A., Ciribilli, Y., and Inga, A. (2015). Whole-genome cartography of p53 response elements ranked on transactivation potential. BMC Genom., 16.","DOI":"10.1186\/s12864-015-1643-9"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ng0492-45","article-title":"Definition of a consensus binding site for p53","volume":"1","year":"1992","journal-title":"Nat. Genet."},{"key":"ref_40","first-page":"2866","article-title":"A transcriptionally active DNA-binding site for human p53 protein complexes","volume":"12","author":"Funk","year":"1992","journal-title":"Mol. Cell. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Jordan, J.J. (2008). Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet., 4.","DOI":"10.1371\/annotation\/13bc83be-2345-401d-b953-f1886e9fbdff"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.8023157","article-title":"Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations","volume":"265","author":"Cho","year":"1994","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/nar\/30.7.1563","article-title":"Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain","volume":"30","author":"Wright","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_44","first-page":"82","article-title":"Pymol: An open-source molecular graphics tool","volume":"40","author":"DeLano","year":"2002","journal-title":"CCP4 Newsl. Protein Crystallogr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/sj.onc.1210291","article-title":"Structure\u2013function\u2013rescue: The diverse nature of common p53 cancer mutants","volume":"26","author":"Joerger","year":"2007","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"20494","DOI":"10.1074\/jbc.M603634200","article-title":"Structure of the p53 Core Domain Dimer Bound to DNA","volume":"281","author":"Ho","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1529\/biophysj.106.077800","article-title":"Cooperative Fluctuations Point to the Dimerization Interface of P53 Core Domain","volume":"91","author":"Kantarci","year":"2006","journal-title":"Biophys. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"21934","DOI":"10.1074\/jbc.M604209200","article-title":"Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains","volume":"281","author":"Ang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"24108","DOI":"10.1074\/jbc.M302458200","article-title":"Kinetic instability of p53 core domain mutants: Implications for rescue by small molecules","volume":"278","author":"Friedler","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrc3711","article-title":"Unravelling mechanisms of p53-mediated tumour suppression","volume":"14","author":"Bieging","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"32020","DOI":"10.1074\/jbc.M110.112110","article-title":"ATP Binding to Hsp90 Is Sufficient for Effective Chaperoning of p53 Protein","volume":"285","author":"Walerych","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1038\/onc.2009.281","article-title":"Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions","volume":"28","author":"Walerych","year":"2009","journal-title":"Oncogene"},{"key":"ref_53","first-page":"161","article-title":"Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action","volume":"1869","author":"Wawrzynow","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) Bioenerg."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Luo, Q., Beaver, J.M., Liu, Y., and Zhang, Z. (2017). Dynamics of p53: A Master Decider of Cell Fate. Genes, 8.","DOI":"10.3390\/genes8020066"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e969653","DOI":"10.4161\/23723548.2014.969653","article-title":"p53 regulation upon genotoxic stress: Intricacies and complexities","volume":"1","author":"Kumari","year":"2014","journal-title":"Mol. Cell. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/cancers7010030","article-title":"p53 Acetylation: Regulation and Consequences","volume":"7","author":"Reed","year":"2014","journal-title":"Cancers"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7150\/ijbs.4283","article-title":"Surf the Post-translational Modification Network of p53 Regulation","volume":"8","author":"Gu","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: All mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/cdd.2017.185","article-title":"Mutant p53 partners in crime","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: One name, many proteins","volume":"26","author":"Prives","year":"2012","journal-title":"Genes Dev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in Cancer: New Functions and Therapeutic Opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1101\/gad.1680508","article-title":"Does control of mutant p53 by Mdm2 complicate cancer therapy?","volume":"22","author":"Prives","year":"2008","journal-title":"Genes Dev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1101\/gad.1941710","article-title":"The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor","volume":"24","author":"Manfredi","year":"2010","journal-title":"Genes Dev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","article-title":"Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome","volume":"119","author":"Lang","year":"2004","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jmb.2017.03.030","article-title":"Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy","volume":"429","author":"Yue","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1535-6108(03)00272-1","article-title":"Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription","volume":"4","author":"Chipuk","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.546","article-title":"Gain of function of mutant p53 by coaggregation with multiple tumor suppressors","volume":"7","author":"Xu","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"28152","DOI":"10.1074\/jbc.M112.340638","article-title":"Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: Implications for cancer","volume":"287","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_71","first-page":"E2634","article-title":"Multisite aggregation of p53 and implications for drug rescue","volume":"114","author":"Wang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/febs.13948","article-title":"Targeting mutant p53 in cancer: A long road to precision therapy","volume":"284","author":"Mantovani","year":"2016","journal-title":"FEBS J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1074\/jbc.M309732200","article-title":"Crystal Structure of a Superstable Mutant of Human p53 Core Domain","volume":"279","author":"Joerger","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1006\/jmbi.1996.0425","article-title":"Structural aspects of the p53 protein in relation to gene evolution: A second look","volume":"260","author":"Soussi","year":"1996","journal-title":"J. Mol. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.onc.1202298","article-title":"Evolutionary conservation and somatic mutation hotspot maps of p53: Correlation with p53 protein structural and functional features","volume":"18","author":"Walker","year":"1999","journal-title":"Oncogene"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8438","DOI":"10.1073\/pnas.96.15.8438","article-title":"Hot-spot mutants of p53 core domain evince characteristic local structural changes","volume":"96","author":"Wong","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/prot.24940","article-title":"R248Q mutation-Beyond p53-DNA binding","volume":"83","author":"Ng","year":"2015","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1074\/jbc.M500179200","article-title":"Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations","volume":"280","author":"Joerger","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1073\/pnas.0607286103","article-title":"Structural basis for understanding oncogenic p53 mutations and designing rescue drugs","volume":"103","author":"Joerger","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1515\/bc.2010.027","article-title":"Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation","volume":"391","author":"Malcikova","year":"2010","journal-title":"Biol. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Gomes, A.S., Trov\u00e3o, F., Pinheiro, B.A., Freire, F., Gomes, S., Oliveira, C., Domingues, L., Rom\u00e3o, M.J., Saraiva, L., and Carvalho, A.L. (2018). The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041184"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jmb.2003.12.005","article-title":"Structural Distortion of p53 by the Mutation R249S and its Rescue by a Designed Peptide: Implications for \u201cMutant Conformation\u201d","volume":"336","author":"Friedler","year":"2004","journal-title":"J. Mol. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1038\/oncsis.2016.8","article-title":"Gain of function of mutant p53: R282W on the peak?","volume":"5","author":"Zhang","year":"2016","journal-title":"Oncogenesis"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acschembio.9b00748","article-title":"Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: The Y220X Paradigm","volume":"15","author":"Bauer","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/carcin\/bgl132","article-title":"Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers","volume":"28","author":"Dearth","year":"2007","journal-title":"Carcinogenesis"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1128\/MCB.18.7.3692","article-title":"Characterization of Structural p53 Mutants Which Show Selective Defects in Apoptosis but Not Cell Cycle Arrest","volume":"18","author":"Ryan","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1107\/S0907444906048499","article-title":"Structure of the human p53 core domain in the absence of DNA","volume":"63","author":"Wang","year":"2007","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/07391102.2012.691364","article-title":"The substitutions G245C and G245D in the Zn2+-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain","volume":"31","author":"Pintus","year":"2013","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1107\/S0907444908003338","article-title":"Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 \u00c5 resolution","volume":"64","author":"Tu","year":"2008","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1021\/bi200192j","article-title":"Structural Effects of the L145Q, V157F, and R282W Cancer-Associated Mutations in the p53 DNA-Binding Core Domain","volume":"50","author":"Calhoun","year":"2011","journal-title":"Biochemistry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1107\/S0907444913020830","article-title":"Structures of oncogenic, suppressor and rescued p53 core-domain variants: Mechanisms of mutant p53 rescue","volume":"69","author":"Wallentine","year":"2013","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.1093\/nar\/gkr386","article-title":"Quaternary structure of the specific p53\u2013DNA complex reveals the mechanism of p53 mutant dominance","volume":"39","author":"Aramayo","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Yamamoto, S., and Iwakuma, T. (2018). Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers, 11.","DOI":"10.3390\/cancers11010004"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","article-title":"The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches","volume":"85","author":"Joerger","year":"2016","journal-title":"Annu. Rev. Biochem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/emboj\/19.3.370","article-title":"Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations","volume":"19","author":"Nikolova","year":"2000","journal-title":"EMBO J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1073\/pnas.0401162101","article-title":"A global suppressor motif for p53 cancer mutants","volume":"101","author":"Baroni","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/emboj\/17.7.1847","article-title":"Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations","volume":"17","author":"Brachmann","year":"1998","journal-title":"EMBO J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: News from the mutant p53 field","volume":"9","author":"Brosh","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1101\/gad.1662908","article-title":"The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss","volume":"22","author":"Terzian","year":"2008","journal-title":"Genes Dev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fonc.2015.00288","article-title":"Targeting Oncogenic Mutant p53 for Cancer Therapy","volume":"5","author":"Parrales","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_102","unstructured":"NIH-ClinicalTrials (2021, April 11). APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03745716."},{"key":"ref_103","unstructured":"NIH-ClinicalTrials (2019, April 11). Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101), Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02433626."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1126\/science.286.5449.2507","article-title":"Pharmacological Rescue of Mutant p53 Conformation and Function","volume":"286","author":"Foster","year":"1999","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1593\/neo.13704","article-title":"p53-stabilizing Agent CP-31398 Prevents Growth and Invasion of Urothelial Cancer of the Bladder in Transgenic UPII-SV40T Mice","volume":"15","author":"Madka","year":"2013","journal-title":"Neoplasia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/sj.onc.1205362","article-title":"Characterization of the p53-rescue drug CP-31398 in vitro and in living cells","volume":"21","author":"Rippin","year":"2002","journal-title":"Oncogene"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molonc.2008.02.004","article-title":"Mutant p53 targeting by the low molecular weight compound STIMA-1","volume":"2","author":"Zache","year":"2008","journal-title":"Mol. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"30384","DOI":"10.1074\/jbc.M501664200","article-title":"Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs","volume":"280","author":"Bykov","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejmech.2015.10.052","article-title":"Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties","volume":"107","author":"Punganuru","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/carcin\/23.12.2011","article-title":"Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database","volume":"23","author":"Bykov","year":"2002","journal-title":"Carcinogenesis"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1038\/sj.onc.1208419","article-title":"PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis","volume":"24","author":"Bykov","year":"2005","journal-title":"Oncogene"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain","volume":"15","author":"Lambert","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/onc.2009.425","article-title":"Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis","volume":"29","author":"Lambert","year":"2009","journal-title":"Oncogene"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/ijc.26228","article-title":"Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells","volume":"130","author":"Messina","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1038\/bjc.2013.635","article-title":"Variability in functional p53 reactivation by PRIMA-1Met\/APR-246 in Ewing sarcoma","volume":"109","author":"Aryee","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"36689","DOI":"10.18632\/oncotarget.5385","article-title":"PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-15-1927","article-title":"Silencing of CD24 Enhances the PRIMA-1\u2013Induced Restoration of Mutant p53 in Prostate Cancer Cells","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_119","first-page":"1","article-title":"APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"E5271","DOI":"10.1073\/pnas.1610421113","article-title":"2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells","volume":"113","author":"Bauer","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1074\/jbc.RA117.000950","article-title":"The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53","volume":"293","author":"Madan","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.freeradbiomed.2010.02.009","article-title":"Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: Differential cytotoxicity in healthy and cancer cells","volume":"48","author":"Selvendiran","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/pro.507","article-title":"Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding","volume":"19","author":"Kaar","year":"2010","journal-title":"Protein Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ccr.2012.03.042","article-title":"Allele-Specific p53 Mutant Reactivation","volume":"21","author":"Yu","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"8879","DOI":"10.18632\/oncotarget.2432","article-title":"Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism","volume":"5","author":"Yu","year":"2014","journal-title":"Oncotarget"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ijrobp.2015.12.272","article-title":"A Novel Third Generation Thiosemicarbazone, COTI-2, Is Highly Effective in Killing Head and Neck Squamous Cell Carcinomas (HNSCC) Bearing a Variety of TP53 Mutations","volume":"94","author":"Silver","year":"2016","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(16)32638-7","article-title":"COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K\/AKT\/mTOR pathway","volume":"69","author":"Salim","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"41363","DOI":"10.18632\/oncotarget.9133","article-title":"COTI-2, a novel small molecule that is active against multiple human cancer cell lines In Vitro and In Vivo","volume":"7","author":"Salim","year":"2016","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1021\/acs.jmedchem.0c01360","article-title":"Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53","volume":"64","author":"Gilleran","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"10360","DOI":"10.1073\/pnas.0805326105","article-title":"Targeted rescue of a destabilized mutant of p53 by an in silico screened drug","volume":"105","author":"Boeckler","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejmech.2018.04.035","article-title":"Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines","volume":"152","author":"Baud","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.4155\/fmc-2019-0181","article-title":"A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C","volume":"11","author":"Bauer","year":"2019","journal-title":"Futur. Med. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1093\/nar\/gkt305","article-title":"Small molecule induced reactivation of mutant p53 in cancer cells","volume":"41","author":"Liu","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1021\/ja301056a","article-title":"Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53","volume":"134","author":"Wilcken","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.18632\/oncotarget.6775","article-title":"Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule","volume":"7","author":"Soares","year":"2016","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"129440","DOI":"10.1016\/j.bbagen.2019.129440","article-title":"SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations","volume":"1864","author":"Gomes","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"574799","DOI":"10.3389\/fcell.2020.574799","article-title":"2-[(4-Hydroxybenzyl) Amino] Phenol (HBAP) Restores the Mutated p53 to the Level Similar to That of Wild-Type p53 Protein and Inhibits Breast Cancer Growth in vivo to by Inducing Tumor Cells Apoptosis","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"108982","DOI":"10.1016\/j.celrep.2021.108982","article-title":"A selective p53 activator and anticancer agent to improve colorectal cancer therapy","volume":"35","author":"Ramos","year":"2021","journal-title":"Cell Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1074\/jbc.M109.083469","article-title":"SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53","volume":"285","author":"Demma","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/ncomms2361","article-title":"Computational identification of a transiently open L1\/S3 pocket for reactivation of mutant p53","volume":"4","author":"Wassman","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_141","first-page":"1276","article-title":"An In Silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53","volume":"16","author":"Malami","year":"2017","journal-title":"EXCLI J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"11817","DOI":"10.18632\/oncotarget.7857","article-title":"Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides","volume":"7","author":"Tal","year":"2016","journal-title":"Oncotarget"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1073\/pnas.241629998","article-title":"A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants","volume":"99","author":"Friedler","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1073\/pnas.1835733100","article-title":"Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide","volume":"100","author":"Issaeva","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.chembiol.2015.07.016","article-title":"Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis","volume":"22","author":"Hiraki","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Gomes, S., Bosco, B., Loureiro, J.B., Ramos, H., Raimundo, L., Soares, J., Nazareth, N., Barcherini, V., Domingues, L., and Oliveira, C. (2019). SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. Cancers, 11.","DOI":"10.3390\/cancers11081151"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1038\/sj.onc.1206777","article-title":"Rescue of mutant p53 transcription function by ellipticine","volume":"22","author":"Peng","year":"2003","journal-title":"Oncogene"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/sj.cdd.4402301","article-title":"A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L\/TRAIL-induced apoptosis","volume":"15","author":"Weinmann","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/cdd.2016.48","article-title":"Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth","volume":"23","author":"Aggarwal","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mc.10038","article-title":"Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1","volume":"33","author":"North","year":"2002","journal-title":"Mol. Carcinog."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1073\/pnas.0802091105","article-title":"Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway","volume":"105","author":"Kravchenko","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1158\/0008-5472.CAN-13-0955","article-title":"Prodigiosin Rescues Deficient p53 Signaling and Antitumor Effects via Upregulating p73 and Disrupting Its Interaction with Mutant p53","volume":"74","author":"Hong","year":"2014","journal-title":"Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.canlet.2019.01.014","article-title":"New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma","volume":"446","author":"Gomes","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/ncb3427","article-title":"DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway","volume":"18","author":"Parrales","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nm.3839","article-title":"Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer","volume":"21","author":"Wei","year":"2015","journal-title":"Nat. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ccell.2015.12.002","article-title":"A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas","volume":"29","author":"Soragni","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1541-7786.MCR-10-0534","article-title":"Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells","volume":"9","author":"Li","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"ref_158","first-page":"352","article-title":"Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment","volume":"523","author":"Alexandrova","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_159","first-page":"933","article-title":"Geldanamycin selectively destabilizes and conformationally alters mutated p53","volume":"11","author":"Blagosklonny","year":"1995","journal-title":"Oncogene"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1074\/jbc.M206697200","article-title":"Phosphorylation and hsp90 Binding Mediate Heat Shock Stabilization of p53","volume":"278","author":"Wang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/cdd.2011.71","article-title":"SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis","volume":"18","author":"Li","year":"2011","journal-title":"Cell Death Differ."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cellsig.2016.02.006","article-title":"Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8\/YY1 signals in triple negative breast cancer cells","volume":"28","author":"Wang","year":"2016","journal-title":"Cell. Signal."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"17478","DOI":"10.1074\/jbc.M111.231639","article-title":"Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression","volume":"286","author":"Yan","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jcb.22941","article-title":"Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP","volume":"112","author":"Wang","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"ref_166","first-page":"718","article-title":"Chaperone-mediated autophagy degrades mutant p53","volume":"27","year":"2013","journal-title":"Genes Dev."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"984","DOI":"10.18632\/oncotarget.1070","article-title":"Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells","volume":"4","author":"Yi","year":"2013","journal-title":"Oncotarget"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1158\/0008-5472.CAN-13-1079","article-title":"Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53","volume":"75","author":"Zhang","year":"2015","journal-title":"Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/carcin\/bgt032","article-title":"Degradation of NF-\u03baB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells","volume":"34","author":"Paranjpe","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/nar\/gky1314","article-title":"Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket","volume":"47","author":"Pradhan","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sbi.2020.11.005","article-title":"An integrated view of p53 dynamics, function, and reactivation","volume":"67","author":"Demir","year":"2021","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1021\/acs.accounts.7b00473","article-title":"Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer","volume":"51","author":"Silva","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tibs.2014.04.001","article-title":"Prion-like aggregation of mutant p53 in cancer","volume":"39","author":"Silva","year":"2014","journal-title":"Trends Biochem. Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:25:35Z","timestamp":1760163935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":173,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cancers13133344"],"URL":"https:\/\/doi.org\/10.3390\/cancers13133344","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]}}}